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Abstract
Enhanced tumor delivery of plasmid DNA with electric pulses in vivo has been confirmed in many
preclinical models. Intratumor electrotransfer of plasmids encoding therapeutic molecules has
reached Phase II clinical trials. In multiple preclinical studies, a reduction in tumor growth,
increased survival, or complete tumor regression have been observed in control groups in which
vector or backbone plasmid DNA electrotransfer was performed. This study explores factors that
could produce this antitumor effect. The specific electrotransfer pulse protocol employed
significantly potentiated the regression. Tumor regression was observed after delivery of single-
stranded or double-stranded DNA with or without CpG motifs in both immunocompetent and
immunodeficient mice, indicating the involvement of the innate immune system in response to
DNA. In conclusion, this study demonstrated that the observed antitumor effects are not due to a
single factor, but to a combination of factors.
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Introduction
Therapeutic gene delivery using electric pulses (electrotransfer) has been achieved in a
variety of tissue types including skin, kidney, liver, testis, brain, cartilage, arteries, prostate,
cornea, and skeletal muscle1, 2. Intratumor electrotransfer of plasmids encoding therapeutic
genes has been developed in preclinical models3, 4 and has been used in veterinary
oncology5 and clinical trials6.
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Interestingly and apparently independent of specific genes, inhibition of tumor growth,
increased survival time, and complete tumor regression have been observed after intratumor
electrotransfer of control plasmids, either plasmid devoid of only therapeutic gene or
plasmids encoding reporter genes to palpable tumors in preclinical models. These effects
have been described in melanomas7–11, lung carcinomas12, 13, fibrosarcomas14, pancreatic
carcinomas15, mammary tumors16 and colorectal carcinomas17, 18. In two studies, antitumor
effects were observed after intratumor electrotransfer of an oligonucleotide containing a
CpG motif, although each oligonucleotide primarily functioned as an antisense
molecule19, 20. The large number of variables between these studies limits the ability to
explore the mechanism of this non-specific tumor regression.
This study explored potential factors that may play a role in this observed antitumor effect in
the well-characterized mouse B16.F10 melanoma tumor model Intratumor plasmid
electrotransfer by four electroporation pulse protocols that varied considerably in pulse
number, length, and field strength was compared12, 21–23. Previous studies confirmed that
application of pulses alone did not induce tumor regression8, 12, 23; combination with DNA
is required. Therefore, the DNA composition was also explored.
Materials and Methods
Tumor and animal models
All procedures were approved by the Institutional Animal Use and Care Committee of the
University of South Florida College of Medicine, Tampa, FL, USA (#R2736) and
Veterinary Administration of The Ministry of Agriculture and the Environment of the
Republic of Slovenia (#34401-12/2009/6). One million B16.F10 (ATCC CR6475) mouse
melanoma cells in 50 µl PBS were injected subcutaneously in the left flank of female 7–8
week old C57Bl/6 (Jackson Laboratories, Bar Harbor, ME) or SCID (Harlan, Udine, Italy)
mice. Tumors were allowed to grow approximately eight days to an approximate diameter of
four mm before manipulation.
Plasmids and oligonucleotides
Plasmids gWizLuc and gWizBlank (Aldevron, Fargo, ND) were commercially prepared
(Aldevron, Fargo, ND). Oligonucleotides were modified by the inclusion of
phosphorothioate internucleotide bonds (IDT DNA, Coralville, IA or Invivogen, San Diego,
CA) to produce nuclease resistance. Oligonucleotide sequences were ODN 1668, 5’-
TCCATGACGTTCCTGATGCT-3’ and ODN 1720, 5’-
TCCATGAGCTTCCTGATGCT-3’24, 25. All molecules were suspended in sterile injectable
saline at 2 mg/ml.
Electrotransfer in vitro
Confluent low passage B16.F10 cells were prepared in electroporation buffer at a
concentration of 25 × 106 cells/mL26. Cells (80 µL of final cell suspension) were mixed with
20 µL of gWizBlank plasmid (1 mg/mL). One half of the mixture was placed between 2 mm
gap steel electrodes and exposed to 8 square wave electric pulses (electric field intensity 600
V/cm, pulse duration 5 ms, frequency 1 Hz). The other half of the mixture served as control
for plasmid exposure without the electric pulses. Electric pulses were generated by in-house
build electroporator (University of Ljubljana, Faculty of Electrical Engineering, Slovenia).
After the application of electric pulses, the cells were incubated at room temperature for 5
min and then plated for cell viability assay. The number of viable cells was determined by
PrestoBlue Cell Viability Reagent (Life Technologies, Carlsbad, CA) according to the
manufacturer’s protocol every 24 hours for four consecutive days. Cell proliferation rate was
quantified by the slope of the linear regression between log10 (cell proliferation) and time.
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Deliveries were performed on day 0 (mean tumor diameter 4 mm), day 3, and day 7. Mice
were anesthetized using a mixture of 2.5% isoflurane and 97.5% O2. Tumors were injected
with 50 µl of molecule solution and pulsed immediately with caliper electrodes moistened
with electrode paste as described in each figure at a frequency of 1 Hz using a T820
Electrosquare porator (BTX Molecular Delivery Systems, Holliston, MA) or a Betatech
Electro cell B10 porator (Betatech, Toulouse, France). Tumors were measured twice to three
times weekly using a digital caliper. Tumor volume was calculated by the standard formula
v=ab2π/6, where a is the longest diameter, and b is the next longest diameter perpendicular
to a. Any animal was considered incurable and humanely euthanized when the tumor
volume reached 1000 mm3 or when the animal’s behavior indicated discomfort. Animals
with tumors in regression were followed up to 100 days after the first electrotransfer. After
that, if no tumor regrowth was observed, animals were considered to be in complete
regression.
Statistical analysis
Comparison of complete long-term regression levels between groups was performed using
Holm Sidak test after one way ANOVA was performed and fulfilled or Dunnett's Method
after Kruskal-Wallis One Way Analysis of Variance on Ranks (SigmaPlot, Systat, San Jose,
CA).
Results
When plasmid DNA was electrotransferred into B16.F10 cells in vitro, a small but
significant decrease in viability was observed (Figure 1a). This effect was not observed with
plasmid addition or pulse application alone. Cell proliferation rate was calculated for each
treatment group, and a significantly reduced cell proliferation rate was observed after
plasmid DNA electrotransfer. Cell proliferation rate was not affected by plasmid exposure or
pulse application alone (Figure 1b).
To determine the relative importance of the electrotransfer pulse protocol to the non-specific
antitumor effect observed in vivo, tumor regression after vector plasmid delivery with four
well-characterized electrotransfer protocols was assessed (Figure 2). Delivery of ten 5 ms
pulses at a field strength of 800 V/cm, generated significant long-term tumor regression
(p<0.05) in 25% of animals. Two other protocols, eight 20 ms pulses at a field strength of
500 V/cm and one 100 ms pulse at a field strength of 667 V/cm also induced a lesser but
statistically significant regression levels (p<0.05). In contrast, application of six 50 ms 150
V/cm pulses did not induce tumor regression.
CpG motif DNA is a well-characterized immunostimulatory agent in the plasmid sequence
that may be responsible for the observed antitumor effect24. Control and CpG
oligonucleotides were delivered to determine if DNA containing this motif would induce
regression of melanomas in immunocompetent C57Bl/6 (Figure 3a) and SCID mice (Figure
3b). In immunocompetent C57Bl/6 mice, electrotransfer of the Type B oligonucleotide
(ODN) 166824, 25, containing a mouse specific motif (GACGTT)27, induced significant
long-term and complete tumor regression in 36% of animals (p<0.05), while simple
injection did not. Injection or electrotransfer of control ODN 1720, lacking this motif, did
not induce regression. Intriguingly, electrotransfer induced long-term and complete tumor
regression (p<0.05) in 20% of immunodeficient SCID animals receiving ODN 1668 (CpG
motif) oligonucleotide and 40% of animals receiving control ODN 1720 (GpC motif)
oligonucleotide. In addition, short term tumor regression was induced by electrotransfer of
either oligonucleotide, apparently resulting in significant tumor growth delay (p<0.05),
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being 15.7 ± 6.0 days after electrotransfer of Type B ODN 1668 and 8.5 ± 2.0 days after
electrotransfer of control ODN 1720.
The typical appearances of tumors treated with electrotransfer of either of oligonucleotides
in SCID mice are shown in Figure 4. When long-term tumor regression was achieved 100
days after electrotransfer of either of the oligonucleotides, only minimal scarring was
observed at the site of electrode position, either completely without residual pigmentation or
with small residual pigmentation at the site of tumor transplantation (Figs. 4 a, b). When
only short-term tumor regression was achieved, the newly formed tumors regrew from the
treated area (Figs. 4c, d). The short term regression was present for longer time in the group
of mice that received Type B ODN 1668 (from 2–27 days) compared to mice that received
control ODN 1720 (2–14 days).
Discussion
This study explored potential factors that may play a role in the antitumor effects observed
in many preclinical studies after intratumor electrotransfer of control plasmids. In vitro,
viability of B16.F10 cells and their proliferation rate were significantly reduced by plasmid
DNA electrotransfer, which was not observed after exposure to plasmid DNA or electric
pulses alone. Reduction of cell viability after application of electric pulses was expected as it
was demonstrated previously that long electric pulses at low electric field strength that were
used in the in vitro experiment affect cell viability28. Since cell proliferation and metabolism
are interconnected via common regulatory pathways29, it is possible that the decrease in cell
proliferation rate is a reflection of changes in cellular metabolism in response to plasmid
DNA. However, this decrease in cell proliferation and viability was not likely to explain the
complete tumor regression observed in vivo.
Different electrotransfer pulse protocols delivering an identical lot and dosage of plasmid
DNA produced different levels of tumor regression. This regression was not related to the
quantity of plasmid successfully delivered as demonstrated by reporter expression30 or to the
pulse energy31, 32, pulse number, pulse intensity or the pulse length. In groups where
regression was observed, a relationship between regression and pulse field strength (R2 = 0.
9976) was observed. The rationale behind this strong association is not clear. However, the
pulse regimen was a significant variable in the generation of tumor regression.
Another possible factor involved in the antitumor effect of control plasmids is the presence
of CpG motifs24 in the plasmid sequence. These motifs are bound by the endosomal toll-like
receptor 9 (TLR9)33, which is found primarily in dendritic and B cells, producing immune
stimulation. The immune stimulation by CpG motif DNA has been utilized as a
monotherapy or in combination therapies in clinical trials for cancer therapies and as vaccine
adjuvants34, 35. In animals with palpable B16.F10 tumors, a survival increase and tumor
growth inhibition was observed after multiple intratumoral36 or peritumoral37 injections of
the Type B ODN 1826, which contains two mouse-specific CpG motifs. Significantly
prolonged survival and tumor growth inhibition were observed in this model when
intraperitoneal injection of Type A ODN 1585 was initiated simultaneously with
intraperitoneal tumor cell injection38. Complete tumor regression was not described in these
studies.
In the study described here, electrotransfer of Type B ODN 1668 produced a significant
antitumor effect in immunocompetent mice and a less pronounced effect in SCID mice. This
difference is likely a consequence of activation of different signaling pathways involved in
the stimulation of immune system39. Specifically, type B CpG oligonucleotides induce
strong B cell activation and moderate NK cell activation40. SCID mice lack functional B-
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cells41, thus no response to B-cell mitogens is expected. However, to some extent, type B
CpG oligonucleotides can activate NK cells42, 43. Hence, the observed antitumor effect in
immunodeficient mice could be mediated through activation of NK cells. However, this
should be confirmed by analysis of cytokine production in response to CpG ODNs in both
types of mice.
In SCID mice, tumor regression was also observed after electrotransfer of the control
oligonucleotide. Although both CpG and control oligonucleotides induced complete tumor
regression in SCID mice, differences were observed between the two groups. Short-term
tumor regression was more pronounced in mice receiving electrotransfer of CpG
oligonucleotides, all mice in the group were tumor free for up to 12 days, while only 70% of
mice were tumor free for up to 12 days after electrotransfer of control oligonucleotides. On
the other hand, tumors regressed in only 20% of SCID mice after electrotransfer of CpG
oligonucleotides as opposed to 40% after electrotransfer of control oligonucleotides. In
previous studies, liposomal-mediated transfection of different oligonucleotides was used for
determination of TLR9 activation. The authors demonstrated activation in response to
oligonucleotides independently of the CpG motif and regardless of their methylation
status44, 45. A switch from CpG to GpC motif in oligonucleotides creates a low affinity
ligand for TLR946 and with natural DNA uptake pathway into the cells their concentration is
too low to activate TLR9. These results support the hypothesis that upon enhanced
endosomal translocation, in our case by electrotransfer, low affinity ligands in endosomes
can reach the threshold concentrations required to drive TLR9 activation44, 45.
Consequently, NK cells are activated and may exert antitumor effectiveness, which was
observed in SCID mice. In any case, tumor regression was observed in SCID mice, so
specific cellular and humoral immunity was not required. The lack of tumor response in
immunocompetent mice after control ODN electrotransfer and its underlying mechanisms
require further experimental studies.
In addition to TLR9 receptors, intracellular DNA can be recognized by several cytoplasmic
double-stranded DNA sensors which, when bound to DNA, activate cascades producing
inflammation and programmed cell death47. The specific ligands for these cytosolic sensors
are not well characterized and may be redundant48. Similar to TLR9, these sensors regulate
type I interferon production and mediate inflammatory responses49. DNA sensors are
compartmentalized within the cell, and electrotransfer may be uniquely situated to activate
both endosomal and cytosolic DNA sensors. Electrotransfer is primarily an endocytosis-
driven process50, 51 although DNA is observed in aggregates and in free form in the
cytoplasm after electrotransfer51, 52. The half-life of cytosolic free DNA is short and
probably is a dead end process as far as gene expression is involved53. However, its
presence may be adequate to activate cytoplasmic DNA sensors. This DNA
compartmentalization after electrotransfer may also explain the lack of correlation between
tumor gene expression and tumor regression30. The production of pro-inflammatory and
chemokines is observed in tumors30 and in muscle54 after DNA electrotransfer. This
upregulation supports the concept that endosomal and/or cytosolic nucleic acid receptors,
potentially including both TRL9 and cytosolic DNA sensors, are activated, generating an
antitumor immune response.
In conclusion, our study confirmed sporadic observations in multiple preclinical tumor
models of non-specific tumor regression after control vector electrotransfer in a single tumor
type and single vector, including its concentration, batch, and diluent. The antitumor effects
after electrotransfer of control vector plasmid DNA were due to multiple factors. Tumor
regression was influenced by the pulse regimen, although the presence of DNA was
required. Sequence motifs in DNA sequences contributed to tumor regression. Still, tumor
regression was observed also in SCID mice after delivery of both CpG and GpC
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oligonucleotides, indicating that innate immune system was likely activated through
signaling pathways of multiple nucleic acid sensors. A basic understanding of the
mechanism by which this regression occurs is important in any tumor electrotransfer
therapy. The knowledge that additional signaling pathways are induced is important in
therapeutic design as it may aid or hinder immune-based or other targeted cancer therapies.
In delivery to other tissues, this understanding will also be important, both in the prediction
of the therapeutic outcome after specific gene delivery, and, if necessary, in designing
method to avoid pathway activation in situations where this induction is not desirable.
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Figure 1. Effect of DNA electrotransfer on cell proliferation in vitro
(a) Electrotransfer of gWizBlank plasmid induced a significant decrease in viability, that
was not observed by plasmid alone or application of electric pulses alone. 20 µg of plasmid
(1 mg/mL) was mixed with 2 × 106 B16.F10 cells and half of this mixture was exposed to
eight 5 ms 600 V/cm electric pulses with a plate electrode, whereas the other half served as
control for plasmid alone. Open circles, untreated; filled circles, electroporation; open
triangles, gWizBlank without pulses; filled triangles, gWizBlank with pulses. ANOVA two
sided, P<0.05 * statistical significance. (b) Electrotransfer of gWizBlank plasmid induced a
significant decrease in cell proliferation rate in comparison to control cells, that was not
observed by plasmid alone or application of electric pulses alone. Bars: mean cell
proliferation rate ± st. error of the mean. One way ANOVA, P<0.05 * statistical
significance, NS not significant.
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Figure 2. Long-term tumor regression after electrotransfer using several pulse protocols
100 µg commercially prepared gWizBlank was delivered by electrotransfer into palpable
melanoma tumors in the flanks of C57Bl/6 mice using various pulse protocols: X, untreated;
filled circles, ten 5 ms 800 V/cm pulses with a caliper electrode (EP A)21; filled diamonds,
eight 20 ms 500 V/cm pulses with a caliper electrode (EP B)12; filled inverted triangles, six
50 ms 150 V/cm pulses with a caliper electrode (EP C)22; filled triangles, one 100 ms 667
V/cm pulse with a caliper electrode (EP D)23. Tumor growth or regression was monitored as
described in methods. n=24 for all groups.
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Figure 3. Long-term tumor regression after electrotransfer of CpG motif oligonucleotides
100 µg oligonucleotide was injected with or without pulses into palpable melanoma tumors
using ten 5 ms 800 V/cm pulses with caliper or plate electrode three times in one week. (a)
C57Bl/6 mice. X, untreated (n=16); filled squares, CpG ODN 1668 with pulses (n=15); open
squares, CpG ODN 1668 without pulses (n=6); filled triangles, GpC ODN 1720 with pulses
(n=15); open triangles, GpC ODN 1720 without pulses (n=6). (b) SCID mice, identical
symbols, n=10 per group. Tumor growth or regression was monitored as described in
methods.
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Figure 4. Tumor regression after electrotransfer of CpG motif oligonucleotides in SCID mice
On day 23 after first electrotransfer of oligonucleotides using ten 5 ms 800 V/cm pulses with
a plate electrode, different outcomes were observed: (a) minimal scarring at the tumor site
after electrotransfer of Type B ODN 1668 and (b) electrotransfer of control ODN1720,
where pigmentation at the site of tumor regression is still present; (c) tumor regrowth at the
tumor site after electrotransfer of Type B ODN 1668; and (d) tumor regrowth was quicker
after electrotransfer of control ODN 1720.
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